Location: Boston
Synced from ClinicalTrials.gov · July 28, 2026
Clinical studies recruiting near Boston
Studies with at least one listed site matching this
location on the public registry. Each page explains the study in plain
language, with locations and study-team contacts.
Clinicians: generate a
printable list for your patient →
A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
Phase 1/Phase 2 · Beth Israel Deaconess Medical Center · Eikon Therapeutics · NCT06907043A Study of Enasidenib in People With T-Cell Lymphoma
Phase 2 · Dana Farber Cancer Institute (Data Collection Only) · Memorial Sloan Kettering Cancer Center · NCT06756308Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)
Phase 3 · Investigative Site US003 · Incyte Corporation · NCT06959225To Investigate the Efficacy of Treatment With Oral NA-921 (Bionetide) Versus Placebo in Females With Rett Syndrome
Phase 3 · Biomed Testing Facility #BIO-10-02115 · Biomed Industries, Inc. · NCT06840496A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combine
Phase 2 · Boston Children's Hospital · Franziska Wachter · NCT05796570The PREDICT Registry:
Phase N/A · Dana-Farber Cancer Institute · PreludeDx · NCT03448926Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Speci
Phase 3 · Massachusetts General Hospital · Corvus Pharmaceuticals, Inc. · NCT06561048A Prospective Longitudinal Observational Cohort Study of Pregnant Women Residing at High Altitude in Bolivia
Phase N/A · Massachusetts General Hospital · Massachusetts General Hospital · NCT07312227Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
Phase 1 · Dana-Farber Cancer Institute · Stelexis BioSciences · NCT06533761A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
Phase 3 · Brigham And Women's Hospital · Janssen Research & Development, LLC · NCT06319820TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidos
Phase 3 · Clinical Trial Site · Alnylam Pharmaceuticals · NCT07223203A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantati
Phase 2/Phase 3 · Brigham & Women's Hospital- Site Number : 8400049 · Sanofi · NCT07412470Product Surveillance Registry
Phase N/A · Medtronic · NCT01524276A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
Phase 3 · Boston Children's Hospital · Novo Nordisk A/S · NCT06612268A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
Phase 1 · Dana-Farber/Massachusetts General Hospital, Inc · PAQ Therapeutics, Inc. · NCT07300150A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With
Phase 3 · Research Site · AstraZeneca · NCT06023589Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplant
Phase 2 · Massachusetts General Hospital · New York Blood Center · NCT01656603Annual Wellness Visits vs GRACE-augmented Annual Wellness Visits For Older Adults With High Needs - Phase 2
NA · Mass General Brigham · Massachusetts General Hospital · NCT07166861Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
Phase 2 · Massachusetts General Hospital · Massachusetts General Hospital · NCT04485286Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL
Phase 1 · Brigham and Women's Hospital · Dana-Farber Cancer Institute · NCT06475235Neoadjuvant Darovasertib in Primary Uveal Melanoma
Phase 3 · Massachusetts General Hospital · IDEAYA Biosciences · NCT07015190ACT Lung Health Intervention: Phase Two
NA · Dana-Farber Cancer Institute · Dana-Farber Cancer Institute · NCT06945120Collection of Samples and Clinical Data From Patients With Amyloid Diseases
Phase N/A · Boston University Cancer Research Center · Boston Medical Center · NCT00898235Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving B
Phase N/A · Eastern Cooperative Oncology Group · National Cancer Institute (NCI) · NCT02610413The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
Phase N/A · Massachusetts General Hospital · Jasper Gerritsen · NCT06118723Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia
Phase 2 · Beth Israel Deaconess Medical Center · Inhye Ahn · NCT06333262NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants W
Phase 3 · Neurocrine Clinical Site · Neurocrine Biosciences · NCT06911112Mitral Valve Screening Survey
Phase N/A · Massachusetts General Hospital · Medstar Health Research Institute · NCT04736667NTS-WBRT in Brain Metastases
Phase 2 · Massachusetts General Hospital Cancer Center · Massachusetts General Hospital · NCT05013892NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and S
Phase 1/Phase 2 · Dana Farber Cancer Institute · St. Jude Children's Research Hospital · NCT06239272
Look up another city
Look up another condition